Please use this identifier to cite or link to this item:
|Title:||Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes.||Austin Authors:||Mo, Allison ;Wood, Erica;Shortt, Jake;Hu, Erin;McQuilten, Zoe||Affiliation:||Transfusion Research Unit, School of Public Health & Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Monash Haematology, Monash Health, Melbourne, Victoria, Australia.
School of Clinical Sciences, Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, Victoria, Australia.
Pharmacy Department, Monash Health, Melbourne, Victoria, Australia.
Transfusion Research Unit, School of Public Health & Preventive Medicine, Monash University, Melbourne, Victoria, Australia.;Monash Haematology, Monash Health, Melbourne, Victoria, Australia.
|Issue Date:||Oct-2023||Date:||2023||Publication information:||European Journal of Haematology 2023-10; 111(4)||Abstract:||This study aimed to describe the burden of thrombocytopenia, supportive care practices, bleeding complications and predictors of bleeding in MDS patients within a large Australian hospital network, to better understand the use and effectiveness of platelet transfusions in MDS. A retrospective cohort study of patients aged ≥18 years with MDS, chronic myelomonocytic leukaemia or MDS/myeloproliferative overlap neoplasm admitted from 2016 to 2018 was conducted. Data were obtained from hospital medical records. One hundred seventy-nine patients (median age 78 years, 61.5% male) were identified. The median platelet count at first admission was 90 × 109 /L. Twenty-eight (15.6%) patients had severe thrombocytopenia (platelet count <20 × 109 /L), of whom nine (32.1%) received prophylactic platelet transfusions, five (17.9%) received tranexamic acid (TXA), seven (25%) received both platelet transfusions and TXA, and seven (25%) received no treatment. Bleeding events requiring hospitalisation occurred in 20 (11.2%) patients. Bleeding was not predicted by presenting platelet count, TXA use, platelet transfusion or anticoagulant/antiplatelet therapies. Three patients died of bleeding, at varying platelet counts (18, 38 and 153 × 109 /L). Thrombocytopenia is common in MDS. Although guidelines recommend otherwise, prophylactic platelet transfusions were commonly used for severe thrombocytopenia. Despite the majority of patients receiving platelet transfusions and/or TXA, 11% developed major bleeding occurring at a wide range of platelet counts.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/33331||DOI:||10.1111/ejh.14049||ORCID:||0000-0002-1923-3133
|Journal:||European Journal of Haematology||PubMed URL:||37452616||ISSN:||1600-0609||Type:||Journal Article||Subjects:||haemorrhage
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 3, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.